Clinical Trial Update: A4250, an IBAT Inhibitor in Pediatric Cholestasis [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for A4250 (IBAT inhibitor) in pediatric cholestasis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholestasis

Drugs mentioned

• A4250 (odevixibat)

Snippet

Sponsor: Albireo | Conditions: Pediatric Cholestasis | Phase 2 | Status: COMPLETED